Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
NCT02229149
Terminated
This randomized phase 2 study will seek to determine the effectiveness of chemotherapy (physician's choice of vinorelbine, taxane \[paclitaxel, docetaxel or nab paclitaxel\] or capecitabine) plus trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus pertuzumab in women with HER2-overexpressing metastatic breast (MBC) that has been previously treated with ado-trastuzumab emtansine (T-DM1) in the metastatic setting.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/29/2022
Locations: 19 Sites, Multiple Locations, Texas
Conditions: Breast Neoplasms, Malignant Tumor of the Breast
Register for Updates
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
NCT02591615
Completed
This is a multicenter randomized phase II to determine if the administration of standard platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell Lung Cancer (NSCLC) will improve the overall response rate (ORR) compared to MK-3475 administered before chemotherapy. Patients will be given Pembrolizumab as maintenance up to 2 years: Carboplatin and paclitaxel or pemetrexed every 3 weeks x 4 cycles followed by pembrolizumab every 3 weeks for up to 2 years. Pembro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2022
Locations: UCSD Moores Cancer Center, La Jolla, California +10 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
NCT02857270
Completed
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2022
Locations: Georgetown University Medical Center, Washington, District of Columbia +12 locations
Conditions: Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
Register for Updates
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
NCT01015222
Completed
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
11/21/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Register for Updates
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
NCT02762981
Completed
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: 038, Scottsdale, Arizona +3 locations
Conditions: Solid Tumors
Register for Updates
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
NCT05245760
Withdrawn
This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/04/2022
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Esophageal Cancer, Esophagogastric Junction Cancer
Register for Updates
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
NCT00807859
Completed
The purpose of this study is to determine if AMG 386 in combination with either paclitaxel and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with HER2-positive locally recurrent or metastatic breast cancer. This is an open-label phase 1b trial and has 2 study parts. Study part 1 is a dose escalation study to determine a tolerable dose of AMG 386 in combination with paclitaxel and trastuzumab (cohort A) or with capecitabine and lapatinib (cohort B). Study part... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/04/2022
Locations: Research Site, Tucson, Arizona +22 locations
Conditions: Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer, Locally Recurrent and Metastatic Breast Cancer, Metastases, Metastatic Cancer, Oncology, Solid Tumors, Tumors
Register for Updates
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
NCT02474173
Terminated
This phase Ib trial studies the side effects and best dose onalespib when given together with paclitaxel in treating patients with triple negative breast cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Onalespib works by blocking proper processing of proteins that are important for cancer growth. This results in inability of these proteins to work properly. Paclitaxel kills breast cancer cells by interfering with their abili... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: University of Kentucky/Markey Cancer Center, Lexington, Kentucky +3 locations
Conditions: Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Register for Updates
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
NCT01779050
Terminated
This phase II trial studies the efficacy of trastuzumab treatment in breast cancer patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors and HER2-expressing bone marrow disseminated tumor cells (DTCs). Administering targeted trastuzumab therapy to these patients may result in the elimination of HER2 expressing disseminated tumor cells and improved disease free survival.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/31/2022
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Neoplasms
Register for Updates
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
NCT01649947
Completed
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine. The standard treatment for lung cancer being used includes 2 chemotherapy drugs, called paclitaxel and carboplatin. Some patients who have a specific type of lung cancer can also receive another drug, a drug that targets blood vessels, called bevacizumab (also known as avastin). Hydroxychloroquine is an FDA approved drug for the treatment of malaria, rheu... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/28/2022
Locations: Robert Wood Johnson University Hospital at Hamilton, Hamilton, New Jersey +1 locations
Conditions: Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
Register for Updates
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
NCT01414608
Completed
This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Exte... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/27/2022
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +325 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Register for Updates
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02562716
Completed
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulat... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/18/2022
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +806 locations
Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Register for Updates